The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects.
Oncoimmunology
; 1(3): 377-379, 2012 May 01.
Article
em En
| MEDLINE
| ID: mdl-22737621
ABSTRACT
The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad application in humans.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article